New

ETF model portfolios designed for real investor needs. Discover →

Advertisement
Advertisement

PBEvsIHEETF Comparison

ETF 1
PBE

Invesco Dynamic Biotechnology & Genome ETF

This fund is part of
BioTech & Genomics
+4.79%
VS
ETF 2
IHE

iShares U.S. Pharmaceuticals ETF

This fund is part of
US Health Care
+0.44%

Invesco Dynamic Biotechnology & Genome ETF (PBE) belongs to the BioTech & Genomics segment. iShares U.S. Pharmaceuticals ETF (IHE) is part of the US Health Care segment. PBE's top 1 sector exposures are Healthcare. In contrast, IHE's top sector exposures are Healthcare and Non-Corporate. PBE is more expensive with a Total Expense Ratio (TER) of 0.59%, versus 0.37% for IHE. PBE is up 24.01% year-to-date (YTD) with +$113M in YTD flows. IHE performs worse with 23.1% YTD performance, and +$505M in YTD flows. Run a side-by-side ETF comparison of PBE and IHE below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.

Find out how industry players manage ETF portfolios.  Discover our library of Model portfolios

PBE vs IHE performance and flow charts

Performance

-6.0-4.0-2.00.02.04.0%Sep 28Oct 5Oct 12Oct 19Oct 26

Cumulative Flows

-120 M-100 M-80 M-60 M-40 M-20 M0 MSep 28Oct 5Oct 12Oct 19Oct 26

Get all the metrics on this page, and more, through a reliable ETF data feed

Daily, global ETF data for advanced analysis or integration into apps (API), from our partner Trackinsight.

Historic performance and flows
Data as of 10/27/2026
1M3MYTD1Y3Y5Y
Perf.
PBE
IHE
+3.48%+0.31%
+12.22%+0.74%
+24.01%+23.10%
+38.47%+39.85%
+95.94%+95.36%
+38.86%+82.88%
Flows
PBE
IHE
-$947K-$119M
+$111M-$36M
+$113M+$505M
+$115M+$669M
+$62M+$694M
+$65M+$759M
Volatility and drawdown
3M1Y3Y5Y
Volatility
PBE
IHE
+21.55%+18.62%
+20.01%+18.67%
+20.60%+17.18%
+22.69%+16.77%
Max drawdown
PBE
IHE
-5.97%-9.67%
-11.70%-9.67%
-22.21%-16.04%
-32.63%-16.12%
Max drawdown duration
PBE
IHE
46d69d
166d69d
324d210d
1468d669d
Trading data

Create an account to view trading data

Join for free
PBE
IHE
Last sale
10/28/2026 at 1:30 PM
$101.87
$103.67
Previous close
10/27/2026
$100.74
$103.35
Consolidated volume
10/27/2026
Average volume
30 days
Average discount or premium
30 days
Average Bid/Ask spread
30 days
Replication quality
Data as of September 30, 2026
1-year trailing difference

Create an account to view replication metrics

Join for free

Create an account to view replication quality

Join for free
PBE
IHE
Tracking error
Tracking difference
1 year cumulative return difference
Best
Worst
Daily return difference
Average
Worst
Advertisement
Main metrics
Last update 10/28/2026 at 1:30 PM
Live
Closed
PBE
IHE
Last price
$101.87
$103.67
1D performance
+1.12%
+0.31%
AuM$438.13 M$1.56 B
E/R0.59%0.37%
Characteristics
PBE
IHE
Management strategyPassivePassive
ProviderInvescoiShares
BenchmarkDynamic Biotech & Genome Intellidex IndexDow Jones U.S. Select Pharmaceuticals Index
N° of holdings3057
Asset classEquitiesEquities
Trailing 12m distribution yield
Join
Join
Inception dateJune 23, 2005May 1, 2006
ESGNoNo
Advertisement
Exposure

Countries

PBE
USA
97.22%
Other
2.78%
IHE
USA
95.75%
Other
4.25%

Sectors

PBE
Healthcare
100%
Other
0%
IHE
Healthcare
99.75%
Other
0.25%
Advertisement

Diversification

PBE

Total weight of top 15 holdings out of 15

63.67%
IHE

Total weight of top 15 holdings out of 15

84.42%

Top 15 holdings

Data as of August 31, 2026
PBE
CareDx, Inc.
5.49%
Amgen, Inc.
5.38%
Regeneron Pharmaceuticals, Inc.
5.26%
Vertex Pharmaceuticals, Inc.
5.21%
Royalty Pharma Plc
4.76%
Biogen, Inc.
4.75%
Gilead Sciences, Inc.
4.61%
United Therapeutics Corp.
3.77%
Omeros Corp.
3.73%
Repligen Corp.
3.57%
Illumina, Inc.
3.54%
Halozyme Therapeutics, Inc.
3.51%
Bio-Techne Corp.
3.41%
Protagonist Therapeutics, Inc.
3.37%
Alnylam Pharmaceuticals, Inc.
3.31%
IHE
Johnson & Johnson
22.45%
Eli Lilly & Co.
20.50%
Merck & Co., Inc.
5.00%
Bristol Myers Squibb Co.
4.84%
Royalty Pharma Plc
4.54%
Pfizer Inc.
4.48%
Viatris, Inc.
4.19%
Zoetis, Inc.
3.82%
Jazz Pharmaceuticals Plc
3.43%
Elanco Animal Health, Inc.
2.61%
Corcept Therapeutics, Inc.
2.36%
Crinetics Pharmaceuticals, Inc.
1.95%
Axsome Therapeutics, Inc.
1.87%
Ligand Pharmaceuticals, Inc.
1.24%
Definium Therapeutics, Inc.
1.12%
Frequently asked questions about PBE and IHE

How have the PBE and IHE ETFs performed in 2026?

As of October 27, 2026, PBE is up 24.01% year-to-date (YTD), while IHE has returned 23.1%. That puts PBE better performer ahead so far this year.

Which ETF is attracting more investor money: PBE or IHE?

Year-to-date, the PBE ETF saw +$113M in flows, compared to +$505M for IHE.

Which ETF is more volatile: PBE or IHE?

Over the past year, PBE had a volatility of 20.01%, while IHE experienced 18.67%.

Which ETF is bigger: PBE or IHE?

As of October 27, 2026, PBE holds $438.13 M in assets under management (AUM), while IHE manages $1.56 B.

What sectors do the PBE and IHE ETFs invest in?

PBE leans toward sectors like Healthcare. Meanwhile, IHE focuses on Healthcare.

What are the top holdings of the PBE ETF and IHE ETF?

PBE top holdings include CareDx, Inc., Amgen, Inc. and Regeneron Pharmaceuticals, Inc.. IHE holds in its top three: Johnson & Johnson, Eli Lilly & Co. and Merck & Co., Inc..

Which ETF is more diversified: PBE or IHE?

PBE holds 30 securities with 63.67% of its assets in the top 15. IHE has 57 securities and a top 15 weight of 84.42%.

Advertisement
Advertisement
Advertisement
New Report

ETFs’ Next Act: From Access to Selection

Global ETF Survey 2026